National Institute of Diabetes and Digestive and Kidney Diseases Notice of Closed Meetings, 6131 [2012-2790]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 25 / Tuesday, February 7, 2012 / Notices
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Lakshmanan Sankaran,
PhD, Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 755, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7799, ls38z@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: February 1, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–2796 Filed 2–6–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases Notice
of Closed Meetings
tkelley on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR09–247
Ancillary Studies in Inflammatory Bowel
Diseases.
Date: March 7, 2012.
Time: 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Ann A Jerkins, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 759, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–2242,
jerkinsa@niddk.nih.gov.
VerDate Mar<15>2010
22:15 Feb 06, 2012
Jkt 226001
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; George M. O’Brien
Kidney Research Core Centers
Date: April 2–3, 2012
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center (7400 Wisconsin
Ave), Bethesda, MD 20814.
Contact Person: Paul A. Rushing, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 747, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8895,
rushingp@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel Program Projects in
Digestive Diseases.
Date: April 2, 2012.
Time: 8 a.m.to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Maria E. Davila-Bloom,
Ph.D., Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 758, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7637, davilabloomm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: February 1, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–2790 Filed 2–6–12; 8:45 am]
BILLING CODE 4140–01–P
NUCLEAR REGULATORY
COMMISSION
DEPARTMENT OF HOMELAND
SECURITY
[NRC–2012–0015]
Memorandum of Understanding
Between the U.S. Nuclear Regulatory
Commission and the Department of
Homeland Security Regarding
Consultation Concerning Potential
Vulnerabilities of the Location of
Proposed New Utilization Facilities;
Revision 1
I. Purpose
This Memorandum of Understanding
(MOU) establishes a process to
implement the provisions of Section 657
of the Energy Policy Act of 2005 (EPA),
Pub. L. 109–58, 119 Stat. 594, 814
(2005). Section 657 states:
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
6131
SEC. 657. DEPARTMENT OF HOMELAND
SECURITY CONSULTATION.
Before issuing a license for a utilization
facility, the Nuclear Regulatory Commission
shall consult with the Department of
Homeland Security concerning the potential
vulnerabilities of the location of the proposed
facility to terrorist attack.
II. Background
Nuclear Regulatory Commission
Pursuant to Section 103 of the Atomic
Energy Act of 1954, as amended, 42
U.S.C. 2133, the U.S. Nuclear
Regulatory Commission (NRC) is
responsible for licensing and regulating
the construction and operation of
commercial nuclear power plants
(known as ‘‘utilization facilities’’) in the
United States to protect the health and
safety of the public and to promote the
common defense and security. In
conducting its review of applications for
such facilities pursuant to the
Commission’s implementing regulations
in Title 10 of the Code of Federal
Regulations (10 CFR) Parts 50 and 52,
the NRC must, among other matters,
determine the suitability of the site for
the proposed facility.
Among the provisions pertaining to
the determination of site suitability,
issues associated with the common
defense and security are, as a general
matter, addressed through the
requirements of 10 CFR 100.21(f). This
provision requires applicants to
demonstrate that the site characteristics
of the proposed location are such ‘‘that
adequate security plans and measures
can be developed.’’ In conducting its
technical review of this portion of the
application, the NRC addresses
potential vulnerabilities of the location
of the proposed facility to terrorist
attack; this evaluation focuses on
assessing the impact of the following
factors: (1) pedestrian and vehicular
land approaches, (2) railroad
approaches, (3) waterborne approaches,
(4) potential ‘‘high-ground’’ adversary
advantage areas, (5) nearby road and/or
transportation routes, and (6) nearby
hazardous materials facilities, airports,
dams, military and chemical facilities,
and pipelines.
Department of Homeland Security
The Department of Homeland
Security (DHS), pursuant to the
Homeland Security Act (HSA) of 2002,
Public Law 107–296, 116 Stat. 2135;
Homeland Security Presidential
Directive 7 (HSPD–7); and the National
Infrastructure Protection Plan of 2006,
has the authority and responsibility to
lead the unified national effort to secure
America by preventing, deterring, and
responding to terrorist attacks and other
E:\FR\FM\07FEN1.SGM
07FEN1
]]>Agencies
[Federal Register Volume 77, Number 25 (Tuesday, February 7, 2012)]
[Notices]
[Page 6131]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-2790]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; PAR09-247 Ancillary
Studies in Inflammatory Bowel Diseases.
Date: March 7, 2012.
Time: 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Ann A Jerkins, Ph.D., Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 759,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-2242,
jerkinsa@niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; George M. O'Brien Kidney
Research Core Centers
Date: April 2-3, 2012
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications
Place: Hyatt Regency Bethesda, One Bethesda Metro Center (7400
Wisconsin Ave), Bethesda, MD 20814.
Contact Person: Paul A. Rushing, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 747, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-8895, rushingp@extra.niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel Program Projects in
Digestive Diseases.
Date: April 2, 2012.
Time: 8 a.m.to 4 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott Suites, 6711 Democracy Boulevard,
Bethesda, MD 20817.
Contact Person: Maria E. Davila-Bloom, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 758, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-7637, davila-bloomm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: February 1, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-2790 Filed 2-6-12; 8:45 am]
BILLING CODE 4140-01-P
